Cargando…

Angiotensin Converting Enzyme Inhibitors versus Receptor Blockers in Patients with Ventricular Tachyarrhythmias

Data investigating the prognostic value of treatment with angiotensin converting enzyme inhibitors (ACEi) and receptor blockers (ARB) usually focusses on patients presenting with heart failure (HF) or acute myocardial infarction (AMI). However, by preventing adverse cardiac remodeling, ACEi/ARB may...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schupp, Tobias, Behnes, Michael, Abumayyaleh, Mohammad, Weidner, Kathrin, Mashayekhi, Kambis, Bertsch, Thomas, Akin, Ibrahim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8910841/ https://www.ncbi.nlm.nih.gov/pubmed/35268553 http://dx.doi.org/10.3390/jcm11051460

Ejemplares similares

Carvedilol versus Metoprolol in Patients with Ventricular Tachyarrhythmias
por: Schupp, Tobias, et al.
Publicado: (2022)

Prognostic value of beta-blocker doses in patients with ventricular tachyarrhythmias
por: Schupp, Tobias, et al.
Publicado: (2022)

Prognostic Value of Cardiac Troponin I in Patients with Ventricular Tachyarrhythmias
por: Akin, Ibrahim, et al.
Publicado: (2022)

Prognostic Impact of Different Types of Ventricular Tachyarrhythmias Stratified by Underlying Cardiac Disease
por: Schupp, Tobias, et al.
Publicado: (2022)

Type 2 diabetes is independently associated with all-cause mortality secondary to ventricular tachyarrhythmias
por: Weidner, Kathrin, et al.
Publicado: (2018)

Statin therapy is associated with improved survival in patients with ventricular tachyarrhythmias
por: Rusnak, Jonas, et al.
Publicado: (2019)

Atrial Fibrillation Is Associated with Increased Mortality in Patients Presenting with Ventricular Tachyarrhythmias
por: Behnes, Michael, et al.
Publicado: (2019)

Electrical storm reveals worse prognosis compared to myocardial infarction complicated by ventricular tachyarrhythmias in ICD recipients
por: Müller, Julian, et al.
Publicado: (2021)

Clinical outcome of out-of-hospital vs. in-hospital cardiac arrest survivors presenting with ventricular tachyarrhythmias
por: Müller, Julian, et al.
Publicado: (2021)

Cardiac disease and prognosis associated with ventricular tachyarrhythmias in young adults and adults
por: Weidner, Kathrin, et al.
Publicado: (2022)

Impact of age on the prognosis of patients with ventricular tachyarrhythmias and aborted cardiac arrest
por: Weidner, Kathrin, et al.
Publicado: (2022)

Prognostic Impact of Acute Myocardial Infarction in Patients Presenting With Ventricular Tachyarrhythmias and Aborted Cardiac Arrest
por: Behnes, Michael, et al.
Publicado: (2018)

Prognostic Value of the AST/ALT Ratio versus Bilirubin in Patients with Cardiogenic Shock
por: Schupp, Tobias, et al.
Publicado: (2023)

Impact of Lactate on 30-Day All-Cause Mortality in Patients with and without Out-of-Hospital Cardiac Arrest Due to Cardiogenic Shock
por: Rusnak, Jonas, et al.
Publicado: (2022)

Differences in Outcome of Patients with Cardiogenic Shock Associated with In-Hospital or Out-of-Hospital Cardiac Arrest
por: Rusnak, Jonas, et al.
Publicado: (2023)

Effect of Cardiovascular Risk Factors on 30-Day All-Cause Mortality in Cardiogenic Shock
por: Forner, Jan, et al.
Publicado: (2023)

Safety and Long-Term Outcomes of Rotablation in Patients with Reduced (<50%) Left Ventricular Ejection Fraction (rEF) (The Rota-REF Study)
por: Ayoub, Mohamed, et al.
Publicado: (2023)

C-Reactive Protein and White Blood Cell Count in Cardiogenic Shock
por: Dudda, Jonas, et al.
Publicado: (2023)

Sex-Based Differences in Rotational Atherectomy and Long-Term Clinical Outcomes
por: Ayoub, Mohamed, et al.
Publicado: (2023)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Gersh, Felice L.
Publicado: (2020)

Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: Anti-arrhythmic Drug for Arrhythmogenic Right Ventricular Cardiomyopathy
por: Tu, Bin, et al.
Publicado: (2021)

Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan
por: Omboni, Stefano, et al.
Publicado: (2018)

In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)

Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
por: Ajmal, Adnan, et al.
Publicado: (2013)

Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide
por: Mamdani, Muhammad, et al.
Publicado: (2019)

Effects of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19
por: Li, Xiao-Long, et al.
Publicado: (2021)

A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers
por: Sadjadi, Seyed Ali, et al.
Publicado: (2009)

A Novel Strategy for Emergency Treatment of Coronary Perforations by Placing a Drug-Eluting Stent before Sealing off the Leakage with a Covered Stent to Improve Long-Term Outcomes in Patients with Coronary Artery Perforations
por: Ayoub, Mohamed, et al.
Publicado: (2023)

Prognostic Value of Different Levels of Uric Acid in Patients with Coronary Chronic Total Occlusion Undergoing Percutaneous Coronary Intervention
por: Ayoub, Mohamed, et al.
Publicado: (2023)

Pneumonia Risk and Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Liu, Chia-Lin, et al.
Publicado: (2013)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
por: Lee, Hyun Woo, et al.
Publicado: (2021)

Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
por: Holloway-Kew, Kara L., et al.
Publicado: (2022)

Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
por: Farid fahmy, Sarah, et al.
Publicado: (2023)

Safety and Efficiency of Rotational Atherectomy in Chronic Total Coronary Occlusion—One-Year Clinical Outcomes of an Observational Registry
por: Ayoub, Mohamed, et al.
Publicado: (2023)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies
por: Kriszta, Gábor, et al.
Publicado: (2021)

Impact of Angiotensin Converting Enzyme Inhibitor versus Angiotensin Receptor Blocker on Incidence of New-Onset Diabetes Mellitus in Asians
por: Park, Ji Young, et al.
Publicado: (2016)

Premorbid Use of Beta-Blockers or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients with Acute Ischemic Stroke
por: Zeng, Yuanyuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cfnq1fajaj6eqquevuri4jko6j